Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.

Psychopharmacology bulletin - 1 Jan 1995

Pollock B G, Mulsant B H, Sweet R A, Rosen J, Altieri L P, Perel J M

Abstract excerpt

Older patients have more adverse experiences when treated with psychotropics than younger patients. Age-associated physiological changes, such as reductions in hepatic mass and blood flow, magnify genetic and acquired variations in drug metabolism. Cytochrome P450 2D6 (debrisoquine hydroxylase), which is responsible for the metabolism of several antidepressants and neuroleptics, is constitutionally deficient in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alzheimer Disease
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dementia

Share to Pharmaceutical Preparations

Share to Phenotype

Share to Psychiatric Status Rating Scales

Share to Time Factors

Source

Identifiers

PMID: 7491387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.PMID 7491387Read ↗

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in DementiaSemantic proximity Read ↗

Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study.Semantic proximity Read ↗

Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.Semantic proximity Read ↗

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.Semantic proximity Read ↗

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

CYP2D6 allelic frequencies in young-onset Parkinson's disease.Semantic proximity Read ↗

Cytochrome P4502D6 (debrisoquine 4-hydroxylase) and Parkinson's disease in Chinese and Caucasians.Semantic proximity Read ↗

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.Semantic proximity Read ↗

Pharmacogenetics of classical and new antipsychotic drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.